Search

Your search keyword '"Vanstraelen, Gaëtan"' showing total 13 results
Start Over Author "Vanstraelen, Gaëtan"
13 results on '"Vanstraelen, Gaëtan"'

1. 10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial

Author

Finke, Jürgen, Schaap, Nicolaas Petrus Michael, Zucenka, Andrius, Metzelder, Stephan, Jost, Edgar, Perić, Zinaida, Forghieri, Fabio, Allione, Bernadino, Martelli, Maurizio, Iori, Anna Paola, Wittnebel, Sebastian, Mengarelli, Andrea, Imovilli, Annalisa, Olivieri, Attilio, De Prijck, Bernard José Marie, van der Poel, Marjolein W.M., Junghanß, Christian, Salih, Helmut Rainer, Tafuri, Agostino, Guimarães, José Eduardo, Musso, Maurizio, De Fabritiis, Paolo, Chevallier, Patrice, Selleslag, Dominik Luc, Cascavilla, Nicola, Berneman, Zwi, Jaspers, Aurélie, Zuffa, Eliana, Vanstraelen, Gaëtan, Visani, Giuseppe, Cuijpers, Maria Louisa Henriëtte, De Becker, Ann, Mianulli, Anna Maria, Hackanson, Björn, Mihaylov, Georgi Georgiev, Martinelli, Giovanni, Paolini, Stefania, Zinzani, Pier Luigi, Henkes, Martin, Al-Ali, Haifa Kathrin, La Rosée, Paul, Chierichini, Anna, Cudillo, Laura, Specchia, Giorgina, Šimec, Njetočka Gredelj, Capalbo, Silvana Franca, Spinosa, Giuseppina, Molica, Stefano, de Jonge-Peeters, Susan Dorothé, Lübbert, Michael, Wijermans, Pierre W, Kicinski, Michal, Chantepie, Sylvain, Van der Velden, Walter J F M, Noppeney, Richard, Griškevičius, Laimonas, Neubauer, Andreas, Crysandt, Martina, Vrhovac, Radovan, Luppi, Mario, Fuhrmann, Stephan, Audisio, Ernesta, Candoni, Anna, Legrand, Olivier, Foà, Robin, Gaidano, Gianluca, van Lammeren-Venema, Danielle, Posthuma, Eduardus F M, Hoogendoorn, Mels, Giraut, Anne, Stevens-Kroef, Marian, Jansen, Joop H, de Graaf, Aniek O, Efficace, Fabio, Ammatuna, Emanuele, Vilque, Jean-Pierre, Wäsch, Ralph, Becker, Heiko, Blijlevens, Nicole, Dührsen, Ulrich, Baron, Frédéric, Suciu, Stefan, Amadori, Sergio, Venditti, Adriano, and Huls, Gerwin

Published
2023
Full Text
View/download PDF

2. Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice—data from a Belgian registry

Author

Devos, Timothy, Havelange, Violaine, Theunissen, Koen, Meers, Stef, Benghiat, Fleur Samantha, Gadisseur, Alain, Vanstraelen, Gaëtan, Vellemans, Hélène, Bailly, Benjamin, Granacher, Nikki, Lewalle, Philippe, De Becker, Ann, Van Eygen, Koen, Janssen, Mia, Triffet, Agnes, Vrelust, Inge, Deeren, Dries, Mazure, Dominiek, Bekaert, Julie, Beck, Michael, and Selleslag, Dominik

Published
2021
Full Text
View/download PDF

3. 10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial

Author

Lübbert, Michael, Wijermans, Pierre W, Kicinski, Michal, Chantepie, Sylvain, Van der Velden, Walter J F M, Noppeney, Richard, Griškevičius, Laimonas, Neubauer, Andreas, Crysandt, Martina, Vrhovac, Radovan, Luppi, Mario, Fuhrmann, Stephan, Audisio, Ernesta, Candoni, Anna, Legrand, Olivier, Foà, Robin, Gaidano, Gianluca, van Lammeren-Venema, Danielle, Posthuma, Eduardus F M, Hoogendoorn, Mels, Giraut, Anne, Stevens-Kroef, Marian, Jansen, Joop H, de Graaf, Aniek O, Efficace, Fabio, Ammatuna, Emanuele, Vilque, Jean-Pierre, Wäsch, Ralph, Becker, Heiko, Blijlevens, Nicole, Dührsen, Ulrich, Baron, Frédéric, Suciu, Stefan, Amadori, Sergio, Venditti, Adriano, Huls, Gerwin, Finke, Jürgen, Schaap, Nicolaas Petrus Michael, Zucenka, Andrius, Metzelder, Stephan, Jost, Edgar, Perić, Zinaida, Forghieri, Fabio, Allione, Bernadino, Martelli, Maurizio, Iori, Anna Paola, Wittnebel, Sebastian, Mengarelli, Andrea, Imovilli, Annalisa, Olivieri, Attilio, De Prijck, Bernard José Marie, van der Poel, Marjolein W.M., Junghanß, Christian, Salih, Helmut Rainer, Tafuri, Agostino, Guimarães, José Eduardo, Musso, Maurizio, De Fabritiis, Paolo, Chevallier, Patrice, Selleslag, Dominik Luc, Cascavilla, Nicola, Berneman, Zwi, Jaspers, Aurélie, Zuffa, Eliana, Vanstraelen, Gaëtan, Visani, Giuseppe, Cuijpers, Maria Louisa Henriëtte, De Becker, Ann, Mianulli, Anna Maria, Hackanson, Björn, Mihaylov, Georgi Georgiev, Martinelli, Giovanni, Paolini, Stefania, Zinzani, Pier Luigi, Henkes, Martin, Al-Ali, Haifa Kathrin, La Rosée, Paul, Chierichini, Anna, Cudillo, Laura, Specchia, Giorgina, Šimec, Njetočka Gredelj, Capalbo, Silvana Franca, Spinosa, Giuseppina, Molica, Stefano, and de Jonge-Peeters, Susan Dorothé

Abstract

Many older patients with acute myeloid leukaemia die or cannot undergo allogeneic haematopoietic stem-cell transplantation (HSCT) due to toxicity caused by intensive chemotherapy. We hypothesised that replacing intensive chemotherapy with decitabine monotherapy could improve outcomes.

Published
2023
Full Text
View/download PDF

4. Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry.

Author

UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Devos, Timothy, Havelange, Violaine, Theunissen, Koen, Meers, Stef, Benghiat, Fleur Samantha, Gadisseur, Alain, Vanstraelen, Gaëtan, Vellemans, Hélène, Bailly, Benjamin, Granacher, Nikki, Lewalle, Philippe, De Becker, Ann, Van Eygen, Koen, Janssen, Mia, Triffet, Agnes, Vrelust, Inge, Deeren, Dries, Mazure, Dominiek, Bekaert, Julie, Beck, Michael, Selleslag, Dominik, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Devos, Timothy, Havelange, Violaine, Theunissen, Koen, Meers, Stef, Benghiat, Fleur Samantha, Gadisseur, Alain, Vanstraelen, Gaëtan, Vellemans, Hélène, Bailly, Benjamin, Granacher, Nikki, Lewalle, Philippe, De Becker, Ann, Van Eygen, Koen, Janssen, Mia, Triffet, Agnes, Vrelust, Inge, Deeren, Dries, Mazure, Dominiek, Bekaert, Julie, Beck, Michael, and Selleslag, Dominik

Abstract

Data on clinical use of ponatinib are limited. This prospective registry aimed to evaluate outcomes of ponatinib treatment in routine practice over 3 years (2016-2019) in Belgium (NCT03678454). Patients with chronic myeloid leukemia (CML) or Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) were treated with ponatinib per current label. Fifty patients (33 CML and 17 Ph+ ALL) were enrolled. Fifty-five percent of CML and 29% of Ph+ ALL patients had received ≥3 prior tyrosine kinase inhibitors (TKIs). Reasons for starting ponatinib were intolerance (40%), relapse or refractoriness (28%) to previous TKIs, progression (16%), or T315I mutation (16%). Median follow-up was 15 months for CML and 4.5 months for Ph+ ALL patients. Best response was a major molecular response in 58% of CML and 41% of Ph+ ALL patients. Of 20 patients who started ponatinib due to intolerance to previous TKIs, 9 (64%) CML and 4 (67%) Ph+ ALL achieved a major molecular response. Three-year estimates of overall survival were 85.3% and 85.6%, respectively, in CML and Ph+ ALL patients; estimated progression-free survival was 81.6% and 48.9%. Adverse reactions were reported in 34 patients (68%); rash (26%) and dry skin (10%) were most common. Reported cardiovascular adverse reactions included vascular stenosis (3), arterial hypertension (2), chest pain (1), palpitations (1), and vascular occlusion (1). This Belgian registry confirms results from the PACE clinical trial and supports routine ponatinib use in CML and Ph+ ALL patients who are resistant or intolerant to previous TKIs or with the T315I mutation.

Published
2021

5. Safety Profile for Lenalidomide-Based and Non-Lenalidomide-Based First-Line Therapy for Multiple Myeloma in Transplant Ineligible Patients: Real-World Evidence from a European Post-Authorization Safety Study

Author

Cavo, Michele, primary, De Stefano, Valerio, additional, Ramirez Payer, Angel, additional, Wiesholzer, Martin, additional, Tromp, Yvonne, additional, Vanstraelen, Gaëtan, additional, Schaedlich, Baerbel, additional, Valentine, Richez, additional, Dhanasiri, Sujith, additional, Kueenburg, Elisabeth, additional, Rosettani, Barbara, additional, Martin, Claire, additional, Pozzi, Stefano, additional, Bacon, Pamela, additional, and Gamberi, Barbara, additional

Published
2019
Full Text
View/download PDF

6. Real-Life Outcomes of Ponatinib Treatment in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Data from a Nationwide Belgian Registry

Author

Devos, Timothy, primary, Havelange, Violaine, additional, Theunissen, Koen, additional, Meers, Stef, additional, Benghiat, Fleur Samantha, additional, Gadisseur, Alain, additional, Vanstraelen, Gaëtan, additional, André, Marc, additional, Bailly, Benjamin, additional, Granacher, Nikki, additional, Lewalle, Philippe, additional, De Becker, Ann, additional, Van Eygen, Koen, additional, Lejeune, Marie, additional, Deeren, Dries, additional, Nifosi, Gianfilippo, additional, Triffet, Agnes, additional, Vrelust, Inge, additional, Bekaert, Julie, additional, Beck, Michael, additional, and Selleslag, Dominik, additional

Published
2019
Full Text
View/download PDF

7. Efficacy and Safety of Ponatinib in CML and Ph+ ALL Patients in Real-World Clinical Practice: Data from a Belgian Registry

Author

Devos, Timothy, primary, Theunissen, Koen, additional, Benghiat, Fleur Samantha, additional, Gadisseur, Alain, additional, Meers, Stef, additional, Selleslag, Dominik, additional, Vanstraelen, Gaëtan, additional, Zachée, Pierre, additional, André, Marc, additional, Lewalle, Philippe, additional, Janssen, Mia, additional, Schots, Rik, additional, Van Eygen, Koen, additional, Kentos, Alain, additional, Lejeune, Marie, additional, Triffet, Agnes, additional, Vrelust, Inge, additional, Kuipers, Carolina, additional, and Havelange, Violaine, additional

Published
2018
Full Text
View/download PDF

13. Efficacy of recombinant human erythropoietin therapy started one month after autologous peripheral blood stem cell transplantation.

Author

Vanstraelen G, Baron F, Frère P, Hafraoui K, Fillet G, and Beguin Y

Subjects
Aged, Female, Hematologic Diseases blood, Humans, Male, Middle Aged, Recombinant Proteins, Transplantation, Autologous, Erythropoietin therapeutic use, Hematologic Diseases surgery, Peripheral Blood Stem Cell Transplantation methods
Abstract

On day 30 after autologous peripheral blood stem cell transplantation (PBSCT), 20 patients were randomized to receive either erythropoietin at a dose of 500 U/kg/week s.c. (Epo group) or no treatment (control group). After 3 weeks, hemoglobin (p<0.0001) and serum transferrin receptor (p<0.0001) concentrations were higher in the Epo group. Hb response (+2 g/dL) was achieved in 100% vs 28% (p<0.0001) and Hb correction (> or =13 g/dL) in 70% vs 10% (p=0.0238) of the patients, respectively. This is the first randomized study showing an efficacy of erythropoietin therapy on Hb levels after autologous PBSCT.

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results